ABSTRACT
Variants of SARS-CoV-2 have been associated with different transmissibilities and disease severities. The present study examines SARS-CoV-2 genetic variants and their relationship to risk for hospitalization, using data from 12,538 patients from a large, multisite observational cohort study. The association of viral genomic variants and hospitalization is examined with clinical covariates, including COVID-19 vaccination status, outpatient monoclonal antibody treatment status, and underlying risk for poor clinical outcome. Modeling approaches include XGBoost with SHapley Additive exPlanations (SHAP) analysis and generalized linear mixed models. The results indicate that several SARS-CoV-2 lineages are associated with increased hospitalization risk, including B.1.1.7, AY.44, and AY.54. As found in prior studies, Omicron is associated with lower hospitalization risk compared to prior WHO variants. In addition, the results suggest that variants at specific amino acid locations, including locations within Spike protein N-terminal domain and in non-structural protein 14, are associated with hospitalization risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work presented in this study was supported solely by MITRE's Independent Research and Development Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at MITRE determined that the study qualified for exempt status under the provisions of 45 CFR Part 46.104(d)(4).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
Deidentified data has been submitted to National COVID Cohort Collaborative (N3C). Available at https://ncats.nih.gov/n3c.
